Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC1416 SAD in Healthy Volunteers
NCT06067490Phase 1Completed
- Sponsor
- Nanjing RegeneCore Biotech Co., Ltd.
- Start
- Jun 2023
- Primary completion
- May 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Nanobodies (VHH)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in asthma comparing RC1416 with Placebo (2 arms). Primary endpoints: Adverse Events up to 92 days, Vital Signs up to 92 days and 3 more. Started Jun 2023; status: completed.
02
Drugs
RC1416
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06067490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06067490.